|
Canada-0-COSMETICS Azienda Directories
|
Azienda News:
- Diagnostics - Global - World Health Organization (WHO)
Diagnostics are the most important tools that empower the health workforce in the identification of diseases or health conditions They allow the initiation of treatments in order to avoid further complications and costly treatments for patients
- WHO publishes new Essential Diagnostics List and urges countries to . . .
To address the lack of access to tests and testing services in multiple countries, WHO since 2018 has published a yearly essential diagnostics list (EDL), a basket of recommended in vitro diagnostics that should be available at point-of-care and in laboratories in all countries to increase timely and life-saving diagnoses The latest edition, published today, includes WHO-recommended COVID-19
- Call for public consultation - Defining the term “diagnostics”
Diagnostics are medical devices that provide information about diseases, physiological status, or health conditions in medicine and public health, with any of the following test purposes: screening, detection, prevention, surveillance, diagnosis or aid to diagnosis, monitoring, prediction, investigation, prognosis, or staging
- In vitro diagnostics - Global - World Health Organization (WHO)
In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself
- Redefining the HIV response in Africa through local production of . . .
To boost supply chain resilience and regional self-reliance, WHO has been actively advocating for locally manufactured quality-assured medicines and diagnostics In 2023, a Kenya-based pharmaceutical company became the first African manufacturer to receive WHO prequalification to produce tenofovir disoproxil fumarate, lamivudine and dolutegravir (TLD), a WHO-recommended first-line
- Global Diagnostics Coalition
The Global Diagnostics Coalition is a WHO managed network, administered and housed within WHO It has 3 objectives: Conduct advocacy activities that raise awareness and increase support of WHO diagnostic leadership and capacity strengthening efforts as essential health services for management of all health conditions Conduct advocacy activities to raise awareness of the essential role of
- Landscape analysis of commercially available and pipeline in vitro . . .
The Landscape analysis of commercially available and pipeline in vitro diagnostics for fungal priority pathogens focuses on commercially available diagnostic products and pipeline diagnostic products for invasive fungal diseases (IFDs) and on the identifiable gaps
- Strengthening diagnostics capacity - World Health Organization (WHO)
Whilst approximately 70% of healthcare decisions are made based on diagnostic test results, only 3–5% of healthcare budgets go to diagnostic services In many countries clinicians don’t have access to basic diagnostic tools or laboratory tests needed to support patients When they are available, vast distances and isolated communities often make testing people extremely difficult
- WHO releases new list of essential diagnostics; new recommendations for . . .
The World Health Organization (WHO) has released its 2023 Essential Diagnostics List (EDL), which is an evidence-based register of in vitro diagnostics (IVD) that supports countries to make national diagnostic choices
- Guidance for post-market surveillance and market surveillance of . . .
Post-market surveillance is a set of activities conducted by manufacturers, to collect and evaluate experience gained from medical devices that have been placed on the market, and to identify the need to take any action Post-market surveillance is a crucial tool to ensure that medical devices continue to be safe and well performing, and to ensure actions are undertaken if the risk of
|
|